
|Videos|April 13, 2018
EGFR+ NSCLC
EGFR+ NSCLC
Advertisement
December 2017
- A 66-year-old Asian woman presents to her PCP complaining of visual disturbances, nausea, fatigue, and sporadic headaches
- History: HTN, managed on candesartan; hyperlipidemia managed on simvastatin; no smoking history
- PE: BP, 148/70; LLL auscultation reveals decreased breath sounds
- CBC: WNL
- Imaging studies:
- MRI of the head demonstrated a right parietal mass at the graywhite junction with vasogenic edema
- CT of chest, abdomen, and pelvis revealed a 3.4-cm mass in the left lower lobe, and several small liver nodules
- CT-guided transthoracic needle biopsy of the lung lesion showed grade 2 adenocarcinoma, acinar
- Molecular testing: EGFR exon 19 deletion
- Staging: T2aN0M1c
- ECOG 1
- The patient was started on osimertinib 80 mg once daily
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5






































